On Aug. 16, 2021, Moderna announced a revised supply agreement with the Government of Canada for up to 105 million doses of Moderna’s COVID-19 vaccine and its booster vaccine candidate, if authorized, for delivery through 2024.

The agreement provides for 20 million doses each year in 2022 and 2023, with an option for an additional 15 million doses each year. For 2024, the agreement provides an option for up to 35 million doses.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. To date, 23 development programs were underway across these therapeutic areas, with 15 programs having entered the clinic.